布地奈德混悬液雾化吸入用于儿童哮喘急性发作的最佳剂量探析(1)
【摘 要】 目的：探究布地奈德混悬液雾化吸入用于儿童哮喘急性发作的最佳剂量，为临床合理用药提供参考。方法：以2018年1月至2019年5月为研究时段，选取此期间铁岭市西丰县妇幼保健院诊治的80例儿童哮喘急性发作患儿为研究对象，依据随机数字表法，随机将研究对象分为两组，即对照组、观察组(每组40例)，全部患儿均接受常规治疗，在此基础上对照组给予0.5mg布地奈德混悬液雾化吸入治疗，观察组给予1.0mg布地奈德混悬液雾化吸入治疗，比较两组患者的临床治疗总有效率和不良反应发生率。结果：观察组的临床总有效率为92.50%，高于对照组的75.00%，差异有统计学意义(P<0.05);观察组不良反应率为7.50%，与对照组的5.00%相比，差异无统计学意义(P>0.05)。结论：在儿童哮喘急性发作期治疗中，高剂量布地奈德混悬液雾化吸入治疗较低剂量效果理想，且不会增加不良反应。
【关键词】 儿童哮喘;急性发作期;布地奈德混悬液;雾化吸入;最佳剂量;临床合理用药
[Abstract] Objective：To explore the optimal dose of budesonide suspension for acute attack of asthma in children， and to provide reference for clinical rational drug use. Methods： From January 2018 to May 2019， atotalof80 cases of children with acute asthma attack diagnosed and treated in Xifeng Maternal and Child Health Hospital in Tieling city were selected as the research objects. According to the random number table method， the research objects were randomly divided into two groups， namely the control group and the observation group (40 cases in each group). All patients received conventional treatmentregimen， on this basis， the control group was given 0.5mg budesonide suspension atomization inhalation treatment， and the observation group was given 1.0mg budesonide suspension atomization inhalation treatment. The total effective rate and adverse reaction rate were comparedbetween the two groups. Results： The clinical total effective rate of the observation group was 92.50%， which was higher than 75.00% of the control group， and the difference was statistically significant (P<0.05); the adverse reaction rate of the observation group was 7.50%， compared with 5.00% of the control group， the difference was not statistically significant (P>0.05). Conclusion： Thehigh-dose budesonide suspension atomization inhalation has an ideal effect in the treatment of acute attack of asthma in children， and it will not increase adverse reactions.
, http://www.100md.com
[Key words]Childhood asthma; Acute attackperiod; Budesonide suspension; Atomization inhalation; Optimal dose; Clinical rational drug use
小儿支气管哮喘临床较为常见，发病后出现呼气延长、气促和阵发性哮鸣等情况，属过敏性呼吸道疾病。目前我国环境污染不断加剧，且居民饮食结构发生明显变化，小兒支气管哮喘临床发病率呈上升趋势，严重威胁婴幼儿身体健康[1]。针对小儿支气管哮喘，临床治疗以糖皮质激素治疗为主，考虑全身糖皮质激素吸入不良反应较多，推荐使用雾化吸入方式，其中布地奈德混悬液应用广泛，但剂量选择尚存争议，仍需进一步探究。笔者探究了布地奈德混悬液雾化吸入用于儿童哮喘急性发作的最佳剂量，做出如下报道。
1 资料与方法
1.1 一般资料
以2018年1月至2019年5月为研究时段，选取此期间本院收治的儿童哮喘急性发作患儿，共80例，随机编号，采取抽签法分对照组、观察组，各40例。对照组男23例，女17例，年龄2～12岁，平均(7.13±2.21)岁，急性病程1～6d，平均(3.73±1.91)d;观察组男22例，女18例，年龄2～13岁，平均(7.54±2.33)岁，急性病程1～7d，平均(3.21±1.55)d。上述资料组间差异无统计学意义，可比较。, 百拇医药(张宏艳)
【关键词】 儿童哮喘;急性发作期;布地奈德混悬液;雾化吸入;最佳剂量;临床合理用药
[Abstract] Objective：To explore the optimal dose of budesonide suspension for acute attack of asthma in children， and to provide reference for clinical rational drug use. Methods： From January 2018 to May 2019， atotalof80 cases of children with acute asthma attack diagnosed and treated in Xifeng Maternal and Child Health Hospital in Tieling city were selected as the research objects. According to the random number table method， the research objects were randomly divided into two groups， namely the control group and the observation group (40 cases in each group). All patients received conventional treatmentregimen， on this basis， the control group was given 0.5mg budesonide suspension atomization inhalation treatment， and the observation group was given 1.0mg budesonide suspension atomization inhalation treatment. The total effective rate and adverse reaction rate were comparedbetween the two groups. Results： The clinical total effective rate of the observation group was 92.50%， which was higher than 75.00% of the control group， and the difference was statistically significant (P<0.05); the adverse reaction rate of the observation group was 7.50%， compared with 5.00% of the control group， the difference was not statistically significant (P>0.05). Conclusion： Thehigh-dose budesonide suspension atomization inhalation has an ideal effect in the treatment of acute attack of asthma in children， and it will not increase adverse reactions.
, http://www.100md.com
[Key words]Childhood asthma; Acute attackperiod; Budesonide suspension; Atomization inhalation; Optimal dose; Clinical rational drug use
小儿支气管哮喘临床较为常见，发病后出现呼气延长、气促和阵发性哮鸣等情况，属过敏性呼吸道疾病。目前我国环境污染不断加剧，且居民饮食结构发生明显变化，小兒支气管哮喘临床发病率呈上升趋势，严重威胁婴幼儿身体健康[1]。针对小儿支气管哮喘，临床治疗以糖皮质激素治疗为主，考虑全身糖皮质激素吸入不良反应较多，推荐使用雾化吸入方式，其中布地奈德混悬液应用广泛，但剂量选择尚存争议，仍需进一步探究。笔者探究了布地奈德混悬液雾化吸入用于儿童哮喘急性发作的最佳剂量，做出如下报道。
1 资料与方法
1.1 一般资料
以2018年1月至2019年5月为研究时段，选取此期间本院收治的儿童哮喘急性发作患儿，共80例，随机编号，采取抽签法分对照组、观察组，各40例。对照组男23例，女17例，年龄2～12岁，平均(7.13±2.21)岁，急性病程1～6d，平均(3.73±1.91)d;观察组男22例，女18例，年龄2～13岁，平均(7.54±2.33)岁，急性病程1～7d，平均(3.21±1.55)d。上述资料组间差异无统计学意义，可比较。, 百拇医药(张宏艳)